India Approves Its First Dengue Vaccine: What to Know

After years of anticipation, India has finally cleared its first dengue vaccine for use — a significant milestone in the country's long fight against a disease that sickens millions each year.

What Was Approved

On July 20, 2026, India's Central Drugs Standard Control Organisation (CDSCO) granted market authorization to Qdenga (TAK-003), a vaccine developed by Japanese pharmaceutical company Takeda.

The approval covers individuals between 4 and 60 years of age, and notably, the vaccine can be given regardless of whether someone has previously been infected with dengue — a meaningful practical advantage, since some earlier dengue vaccine candidates required pre-vaccination testing to confirm prior infection before they could be safely administered.

Qdenga is given as two subcutaneous injections spaced three months apart, and it's designed to protect against all four dengue virus serotypes, addressing one of the biggest challenges in dengue prevention: the virus's multiple distinct strains, any of which can cause illness.

The Evidence Behind the Approval

India's regulatory decision was backed by a substantial body of clinical research. Takeda's global development program for the vaccine included 19 Phase I, II, and III clinical trials involving more than 28,000 participants across both dengue-endemic and non-endemic countries.

Indian regulators specifically reviewed data from the Phase III DEN-302 trial conducted within India, which tracked participants for more than seven years and continued to show protection against dengue infection and dengue-related hospitalization across all four serotypes throughout that extended follow-up period.

Qdenga isn't new to the global market — it's already been approved in 42 countries, including the European Union, the United Kingdom, Switzerland, and Indonesia, with more than 24 million doses administered worldwide to date.

Manufacturing and Availability in India

Takeda has partnered with Hyderabad-based Biological E to scale up local manufacturing of the vaccine within India, a move expected to support both domestic supply and potential future exports, aligning with the government's broader push for greater self-reliance in vaccine production.

A private-market rollout is anticipated in early 2027, though government procurement discussions and pricing details have not yet been finalized.

India's Own Vaccine Is Close Behind

Alongside the Qdenga approval, India is also developing its own homegrown dengue vaccine. Panacea Biotec's candidate, DengiAll, has entered the final stage of clinical trials, building on Phase 1 and 2 results completed in 2018–19 and a Phase 3 trial that began in 2024 across 19 sites in 18 Indian states and union territories, conducted in partnership with the Indian Council of Medical Research (ICMR).

What makes DengiAll particularly notable is its dosing: unlike Qdenga's two-shot regimen, DengiAll is designed as a single-dose vaccine, which — if approved — would make it one of the first single-dose dengue vaccines available anywhere in the world, potentially easing logistics significantly in remote areas or large-scale vaccination drives.

The vaccine has reportedly shown 100% efficacy in an early human challenge study, alongside a balanced immune response across all four dengue serotypes in earlier trial phases.

Why This Matters for India

Dengue has become an escalating public health concern in India in recent years, with case numbers fluctuating sharply — including a 333% surge between 2020 and 2021 alone, according to data from the National Center for Vector Borne Diseases Control.

Rising temperatures and increasingly dense urban populations have been cited as key factors fueling dengue's global expansion, conditions that apply directly to much of India's rapidly urbanizing landscape.

Health experts have been clear, though, that a vaccine alone won't eliminate the disease. Effective dengue control still depends on sustained mosquito-control programs, community cleanup efforts to eliminate breeding sites, stronger diagnostic capacity, and hospital surge planning for outbreak periods — with vaccination serving as one additional tool in a broader public health strategy rather than a standalone solution.

The Takeaway

India's approval of Qdenga marks a genuine turning point after years of dengue vaccine development efforts, and the arrival of a potential single-dose, India-made alternative in DengiAll suggests the country's options will only expand from here.

For a disease that affects millions annually and has grown more unpredictable with shifting climate and urban conditions, having a genuine vaccination option — with a second, homegrown candidate close behind — represents real progress, even as officials emphasize it's one piece of a much larger public health puzzle.